Boston Scientific (BSX) Research & Development (2009 - 2026)

Boston Scientific (BSX) has 18 years of Research & Development data on file, last reported at $516.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 16.48% year-over-year to $516.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 billion (up 25.59% YoY), and the FY2025 full-year result was $2.1 billion, up 27.06% from the prior year.
• Research & Development declined to $516.0 million in Q1 2026, from $569.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $569.0 million in Q4 2025 to a low of $319.0 million in Q1 2022.
• A 5-year average of $407.1 million and a median of $366.0 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development advanced 3.12% in 2022 and soared 37.34% in 2025, its largest moves.
• Tracing BSX's Research & Development over 5 years: stood at $330.0 million in 2022, then rose by 10.0% to $363.0 million in 2023, then gained by 26.45% to $459.0 million in 2024, then gained by 23.97% to $569.0 million in 2025, then declined by 9.31% to $516.0 million in 2026.
• Business Quant data shows BSX's Research & Development at $516.0 million in Q1 2026, $569.0 million in Q4 2025, and $514.0 million in Q3 2025.